ArticleTranslational lung cancer research2022
Prognostic significance of procalcitonin in small cell lung cancer.
Article in Translational lung cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- [Abnormally Elevated Procalcitonin in Stage IV Lung Adenocarcinoma with Neuroendocrine Differentiation: A Case Report and Literature Review].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Exploring the key clinical and computed tomography features for distinguishing high-grade lung cancers from morphologically similar benign tumors: a two-center case-control study.BMC medical imaging · 2026Article
- Dynamic procalcitonin-guided antibiotic stewardship among cancer patients in the UK.Journal of medical microbiology · 2026Article
- Case Report: Marked elevation of serum procalcitonin before radiographic confirmation of recurrence in stage IVB pulmonary large cell neuroendocrine carcinoma.Frontiers in medicine · 2026Article
- Predictive value of systemic immune-inflammatory markers for lung cancer-associated cerebral infarction: a retrospective cohort study.American journal of cancer research · 2026Article
- Prediction of Lung Cancer Metastasis Using Machine Learning Models Based on Clinical Laboratory Data.Cancer reports (Hoboken, N.J.) · 2025Article
- Highly elevated sepsis biomarkers in advanced cholangiocarcinoma without sepsis: A case report and literature review.Medicine · 2025Review
- Procalcitonin: Infection or Maybe Something More? Noninfectious Causes of Increased Serum Procalcitonin Concentration: Updated Knowledge.Life (Basel, Switzerland) · 2025Review
- Prognostic roles of hematological indicators in programmed cell death protein 1/programmed cell death ligand 1 inhibitors for small-cell lung cancer: a retrospective cohort study.Journal of thoracic disease · 2024Article
- Prognostic Value of Pentraxin3 Protein Expression in Human Malignancies: A Systematic Review and Meta-Analysis.Cancers · 2024Review
- Prognostic value of baseline clinicopathological characteristics in first-line chemotherapy ± immunotherapy for extensive-stage small cell lung cancer: a retrospective cohort study.Journal of thoracic disease · 2024Article
- Prognostic value of post-operative serum procalcitonin in gastric adenocarcinoma patients undergoing radical gastrectomy: propensity score matching analysis of extended cohort from a prospective bi-center study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023Article
- Tricky sepsis biomarker: Extremely high procalcitonin in squamous cell lung cancer with doubtful infection.Respirology case reports · 2023Article
- Efficacy of TACE Combined with Lenvatinib Plus Sintilimab for Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and/or Right Atrium.Journal of hepatocellular carcinoma · 2023Article
- Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib Plus Humanized Programmed Death Receptor-1 in Patients with High-Risk Advanced Hepatocellular Carcinoma: A Real-World Study.Journal of hepatocellular carcinoma · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProcalcitonin (PCT) is a serological marker whose utility has been established in infectious disease areas. Although serum calcitonin is a prognostic predictor in patients with medullary thyroid carcinoma, the clinical usefulness of PCT remains unclear in lung cancer patients.
methodsAs a discovery cohort, we retrospectively analyzed consecutive patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who received first-line chemotherapy at our institution, and PCT blood levels were measured. As the validation cohort, PCT blood levels were prospectively evaluated in SCLC patients before first-line chemotherapy. The correlation between a PCT increase and prognosis was examined in the discovery and validation cohorts.
resultsTwenty-three SCLC patients and 26 NSCLC patients were enrolled as the discovery cohort, and 30 SCLC patients were enrolled as the validation cohort. The PCT level in SCLC patients was significantly higher than that in NSCLC patients. The PCT level was not associated with WBC count and weakly associated with the CRP level. In both the discovery and validation cohorts, the median survival time was significantly shorter in SCLC patients with PCT-high than in SCLC patients with PCT-normal (discovery; 11.7
conclusionsIt may be difficult to differentiate bacterial infections in SCLC patients by PCT, as PCT is elevated even in SCLC patients without infectious diseases. This is the first study to prospectively verify that pretreatment PCT levels have a significant negative correlation with prognosis in SCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.